title: Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.
abstract: OBJECTIVE
  Gemcitabine and capecitabine (gem-cap), gemcitabine and erlotinib (gem-e), and folfirinox (5-fluorouracil-leucovorin-irinotecan-oxaliplatin) are new treatment options for metastatic pancreatic cancer, but they are also more expensive and potentially more toxic than gemcitabine alone (gem). We conducted a cost-effectiveness analysis of these treatment options compared with gem.
  
  
  METHODS
  A Markov model was constructed to examine costs and outcomes of gem-cap, gem-e, folfirinox, and gem in patients with metastatic pancreatic cancer from the perspective of a government health care plan. Ontario health economic and costing data (2010 Canadian dollars) were used. Efficacy data for the treatments were obtained from the published literature. Resource utilization data were derived from a chart review of consecutive metastatic patients treated for pancreatic cancer at Princess Margaret Hospital, Toronto, Ontario, 2008-2009, and supplemented with data from the literature. Utilities were obtained by surveying medical oncologists across Canada using the EQ-5D. Incremental cost-effectiveness ratios (icers) were calculated.
  
  
  RESULTS
  The icers for gem-cap, gem-e, and folfirinox compared with gem were, respectively, CA$84,299, CA$153,631, and CA$133,184 per quality-adjusted life year (qaly). The model was driven mostly by drug acquisition costs. Given a willingness-to-pay (wtp) threshold greater than CA$130,000/qaly, folfirinox was most cost-effective treatment. When the wtp threshold was less than CA$80,000/qaly, gem alone was most cost-effective. The gem-e option was dominated by the other treatments.
  
  
  CONCLUSIONS
  The most cost-effective treatment for metastatic pancreatic cancer depends on the societal wtp threshold. If the societal wtp threshold were to be relatively high or if drug costs were to be substantially reduced, folfirinox might be cost-effective.
authors.affiliation: Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON. ; Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB.
authors.forename: V C
authors.initials: VC
authors.lastname: Tam
authors.forename: Y J
authors.initials: YJ
authors.lastname: Ko
authors.forename: N
authors.initials: N
authors.lastname: Mittmann
authors.forename: M C
authors.initials: MC
authors.lastname: Cheung
authors.forename: K
authors.initials: K
authors.lastname: Kumar
authors.forename: S
authors.initials: S
authors.lastname: Hassan
authors.forename: K K W
authors.initials: KK
authors.lastname: Chan
keywords: Pancreatic cancer; chemotherapy; cost-effectiveness
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2607-15
references.pmid: 17577041
references.citation: J Clin Oncol. 2007 May 20;25(15):1960-6
references.pmid: 17452677
references.citation: N Engl J Med. 2011 May 12;364(19):1817-25
references.pmid: 21561347
references.citation: J Clin Oncol. 2007 Oct 1;25(28):4506-7; author reply 4508
references.pmid: 17906218
references.citation: CMAJ. 1992 Feb 15;146(4):473-81
references.pmid: 1306034
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4149-53
references.pmid: 20697077
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5513-8
references.pmid: 19858379
references.citation: Curr Oncol. 2014 Feb;21(1):e41-51
references.pmid: 24523620
references.citation: J Clin Oncol. 1997 Jun;15(6):2403-13
references.pmid: 9196156
references.citation: Cancer. 2010 Feb 1;116(3):742-8
references.pmid: 20029970
references.citation: Pharmacoeconomics. 2007;25(5):365-84
references.pmid: 17488136
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3617-22
references.pmid: 20606091
references.citation: Palliat Med. 2010 Jul;24(5):523-32
references.pmid: 20348270
references.citation: J Rheumatol. 2001 Mar;28(3):648-56
references.pmid: 11296976
references.citation: J Clin Oncol. 2010 Aug 1;28(22):3605-10
references.pmid: 20606093
references.citation: Circulation. 1996 Sep 1;94(5):957-65
references.pmid: 8790032
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2212-7
references.pmid: 17538165
references.citation: J Gen Intern Med. 1998 Oct;13(10):716-7
references.pmid: 9798822
references.citation: J Clin Oncol. 2012 Apr 20;30(12):1316-20
references.pmid: 22430267
references.citation: BMC Cancer. 2008 Mar 28;8:82
references.pmid: 18373843